Shots:

• Pfenex to receive $2.5M as upfront and milestones for EU & MENA- milestones for ROW & 60% profit split on sales. Alvogen’s subsidiary Theramex & SAJA to get rights to develop and commercialize in EU- Switzerland & MENA respectively (Ex-Mainland China- Hong Kong- Singapore- Malaysia and Thailand) undisclosed in ROW
• On 11 Jun-2018 Pfenex & Alvogen collaborated for the development and commercialization of Pfenex’s PF708 in the US
• Pfenex’s PF708 (teriparatide- biosimilar) is evaluated in P-III study for patients with osteoporosis and is expected to be approved by the US FDA in Q4’19

Ref: Pfenex | Image: Twitter